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Abstract
Multicentre clinical trials involving a dosimetry component are becoming more prevalent in molecular radiotherapy and are essential to generate the evidence
to support individualised approaches to treatment planning and to ensure that sufficient patients are recruited to achieve the statistical significance required.
Quality assurance programmes should be considered to support the standardisation required to achieve meaningful results. Trials should be designed to ensure
that dosimetry results from image acquisition systems across centres are comparable by incorporating steps to standardise the methodologies used for the
quantification of images and dosimetry. Furthermore, it is essential to assess the expertise and resources available at each participating site prior to trial
commencement. A quality assurance plan should be drawn up and training provided if necessary. Standardisation of quantification and dosimetry method-
ologies used in a trial are essential to ensure that results from different centres may be collated. In addition, appropriate uncertainty analysis should be carried
out to correct for differences in methodologies between centres. Recommendations are provided to support dosimetry studies based on the experience of
several previous and ongoing multicentre trials.
 2020 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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Introduction
Most molecular radiotherapy (MRT) treatments are given
with afixed activity administration of radioisotope, accepting
that thiswill lead to awide range of absorbed doses delivered
both to tumours and to organs at risk. Patient dosimetry is
seldom carried out either to predict or verify the radiation
doses delivered. This is in marked contrast to external beam
radiotherapy (EBRT) and brachytherapy [1]. AsMRT becomes
recognised as a form of systemic radiotherapy rather than
conventional chemotherapy, the prospect of personalised
treatment planning and optimisation based on patient
dosimetrymust be considered. Due to radiobiological factors,
in particular the range of radiation emissions, relative bio-
logical effectiveness, heterogeneous dose distribution [2] and
dose rate effects [3], absorbed doses delivered from MRT
cannot be directly correlated to, for example, the absorbed
dose delivered from a 2 Gy per fraction course of EBRT.
Treatment regimens therefore cannot be readily adapted
from conventional protocols used for EBRT. Single centres are
seldom able to recruit sufficient patients to achieve the sta-
tistical significance required to report on study end points
[4,5]. Large prospective, randomised, multicentre studies are
therefore required to show the value of personalised treat-
ment planning in MRT [6].
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The Evidence for Dosimetry
The potential for dosimetry-based treatment planning
has been shown for many therapy procedures [6]. Correla-
tions between absorbed doses and clinical outcomes
following MRT have been reported for several radiophar-
maceuticals in single-centre clinical studies, aided by the
wide range of absorbed doses delivered [7]. Dewaraja et al.
[8] found that mean tumour absorbed doses correlated with
improved progression-free survival after 131I-tositumomab
radioimmunotherapy. Wierts et al. [9] used pre-therapy 124I
positron emission tomography/computed tomography
(PET/CT) lesion dosimetry in thyroid cancer patients treated
with a fixed activity of 131I-NaI and observed a
doseeresponse relationship for thyroid remnants and me-
tastases. A correlation of absorbed dose with successful
ablation was also shown for thyroid cancer treated with
radioiodine [10]. Ilan et al. [11] found a significant correla-
tion between tumour absorbed doses and tumour
shrinkage for pancreatic neuroendocrine tumours treated
with 177Lu-DOTATATE. Violet et al. [12] observed a signifi-
cant correlation between whole-body tumour dose and
prostate-specific antigen response in metastatic castration-
resistant prostate cancer patients treated with 177Lu-PSMA-
617. Barone et al. [13] showed that kidney toxicity after 90Y-
DOTATOC therapy is absorbed dose dependent.
Multicentre Clinical Trials Incorporating
Dosimetry
Although a large number of clinical trials for new and
established radiopharmaceuticals have implemented
dosimetry, a recent survey found that MRT practice across
Europe varies significantly, especially with respect to the
implementation of personalised treatment based on
dosimetry [1]. Collation of results from multiple centres in
MRT dosimetry trials requires standardised quantitative
single photon emission computed tomography(/computed
tomography) SPECT(/CT) acquisitions [14].
In recent years, significant efforts have been made to
improve quantification for gamma camera imaging [15e17]
and work has started on the standardisation of quantifica-
tion in MRT. Zimmerman et al. [18] carried out an interna-
tional comparison of the activity measurement of 177Lu. In a
later study, they evaluated the accuracy and reproducibility
of activity quantification of planar and SPECT imaging in a
multicentre setting with an IAEA phantom study for 133Ba,
which was used as a surrogate for 131I [19]. Peters et al. [20]
carried out phantom measurements as part of a multi-
vendor and multicentre study to assess the quantitative
accuracy and inter-system variability of SPECT/CT systems.
Both Zimmerman et al. [18,19] and Peters et al. [20] found
that absolute SPECT quantification in a multicentre, multi-
national setting is feasible, but that standardisation of im-
age acquisition, reconstruction parameters and processing
is key. Wevrett et al. [21] carried out an international inter-
comparison exercise for quantitative imaging of 177Lu to
investigate consistency between clinical sites. Gregory et al.
[22] and Taprogge et al. [23] established networks of centres
able to carry out standardised radioiodine activity
quantification.
H€anscheid et al. [24] carried out an international, pro-
spective, controlled, randomised study of radioiodine
ablation for differentiated thyroid cancer to compare
stimulation with recombinant human thyroid stimulating
hormone and thyroid hormone withdrawal. Standardised
acquisition and processing protocols were used and
dosimetry results calculated at a central dosimetry hub.
S€undlov et al. [25] carried out a phase II, multicentre,
prospective clinical trial using 177Lu-DOTATATE to treat
metastatic neuroendocrine tumours in two centres in
Sweden.
Recent examples of multicentre MRT clinical trials that
involved standardisation of the acquisition and recon-
struction parameters with centralised dosimetry are SEL-I-
METRY [22,26,27] and MEDIRAD [23]. SEL-I-METRY
(EudraCT no. 2015-002269-47) is a phase II clinical trial to
investigate the potential of selumetinib in resensitising
patients with advanced iodine refractory differentiated
thyroid cancer to radioiodine. Uniquely, the SEL-I-METRY
trial implemented a quality assurance programme in asso-
ciation with the UK Radiotherapy Trials Quality Assurance
(RTTQA) Group to achieve standardisation across the cen-
tres in the trial. MEDIRAD is a European Commission Ho-
rizon 2020-funded project. Work package 3 (WP3) within
MEDIRAD aims to measure the range of absorbed doses
delivered to healthy organs from radioiodine ablation of
thyroid cancer. A linked prospective observational study in
the UK (INSPIRE, NCT04391244) is at the stage of initial





Multicentre dosimetry trials require careful planning to
ensure that data can be collected, stored and directly
compared. Standardisation of image quantification and
dosimetry methods with appropriate uncertainty analysis
is essential. Systematic or random errors in the quantifi-
cation, outlining and dosimetry calculations due to
imperfect equipment calibrations and differences in pro-
cessing of data may lead to large uncertainties in the
calculated absorbed doses [28]. This could potentially
result in a doseeresponse relationship not being detected
or a bias of the data used for the analysis of end points of
the clinical trial. Data transfer and storage must be set up
to ensure that essential information stored in DICOM tags
and non-DICOM data are available for dosimetry process-
ing and review of data as part of a centralised quality
assurance programme. The following recommendations
are provided to facilitate the successful preparation and
running of multicentre MRT studies that incorporate
dosimetry, based on the experience of the multicentre SEL-
I-METRY and MEDIRAD trials in the UK and mainland
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Europe. These recommendations are generated with the
guidance and extensive experience of radiotherapy quality
assurance for multinational EBRT trials.
Trial Quality Assurance Programme
Recommendation 1: MRT clinical trials involving a
component of dosimetry should incorporate a clinical trials
quality assurance programme similar to that in place for
EBRT.
Clinical trials quality assurance programmes help to
ensure that trial data are collected and documented
following the trial protocol, good clinical practice and other
relevant guidance [29e31]. For MRT clinical trials involving
dosimetry, the trial quality assurance should consist of a set
of planned, systematic activities to minimise bias due to
variations in the dosimetry results from different centres.
This should include a site set-up or facility questionnaire
and standard operating procedures (SOPs) for site set-up
and dosimetry calculations [32]. Examples of site set-up
SOPs were published by Gregory et al. [22] in the supple-
mentary material. Furthermore, trial monitoring activities
should be defined to ensure adherence to trial protocols at
all stages throughout the clinical trial. Protocol deviations
from SOPs can be minimised by a case-by-case check of the
imaging and reconstruction parameters at a central
dosimetry hub [33].
Although clinical trials quality assurance programmes
are routine practice in EBRT [34,35], through the Global
Quality Assurance of Radiation Therapy Clinical Trials
Harmonization Group, RTQA [36] and the Radiotherapy
Trials Quality Assurance (RTTQA) Group in the UK, further
work is required to implement similar quality assurance
programmes in all MRT dosimetry clinical trials. MRT can
benefit from the experience gathered in EBRT regarding the
set-up and running of multicentre clinical trials involving
dosimetry.
Site Set-up/Facility Questionnaires
Recommendation 2: Communication should be facili-
tated between key staff at each centre to promote sharing of
experience and resources.
The expertise and resources available at each centre,
including medical physics support, experience with MRT
dosimetry, gamma camera availability and ancillary equip-
ment required (i.e. radionuclide calibrators) should be
assessed with site set-up/facility questionnaires. The ques-
tionnaire should identify key local personnel/staff in the
multiprofessional team, including a named medical physi-
cist to assist with site set-up measurements, quality control
procedures and data handling. All key local personnel/staff
should be informed about progress of essential stages in the
set-up and running of the clinical trial through regular
communications and conference calls. The responses from
the questionnaire will identify centres or individuals that
may require further training or support for the site set-up
measurements at each centre.
Standardisation of Imaging Acquisition Protocols
Recommendation 3: Image acquisition and dosimetry
protocols should be standardised as far as reasonably
practicable allowing for differences in local availability of
resources such as SPECT or SPECT/CT systems.
Absorbed dose calculations require serial imaging over
several days following therapy. Patients may therefore be
asked to make multiple return visits to hospital for further
imaging, which can also have resource implications for
nuclear medicine departments in terms of both staff and
equipment time. In contrast to EBRT, dosimetry procedures
are currently often not reimbursed. The requirement for
significant additional imaging can therefore increase the
costs of academic trials. These factors stress the need for
high-quality studies to justify the additional resource re-
quirements to acquire dosimetric information.
Standardisation of Quantitative SPECT in a Multicentre
Setting
Recommendation 4: Gamma camera calibration meth-
odologies and image acquisition and reconstruction pro-
tocols should be standardised across clinical trials.
Site set-up measurements are essential for clinical
studies involving quantitative imaging. These may include
system volume sensitivity calibrations, partial volume cor-
rections and dead-time characterisation. System volume
sensitivity is defined as the system’s count-rate for a uni-
form concentration of activity. SPECT recovery coefficients
are necessary to correct the observed activity concentration
in tomographic imaging for partial-volume and resolution
effects [37]. Dead-time factors are applied to correct the
observed count-rate of the system for count losses due to
detector paralysis at high imaged activity levels.
Experience from multicentre MRT clinical trials [22,23]
have shown that such measurements may need to be
adapted locally based on radiation protection guidance in
different countries and centres. It is essential to ensure that
the complexity and time required for such measurements
are adapted as necessary, particularly for centres with
limited resources.
National metrology institutes play a key role in EBRT to
ensure delivery of accurate absorbed doses. Accurate ac-
tivity measurements are essential for MRT absorbed dose
calculations. Traceability of activity measurements is
currently not an essential requirement in many countries,
but will play an important role to achieve comparable
dosimetry results from different centres [14].
Logistics of Data Transfer
Recommendations 5: Appropriate data transfer facilities
for both image DICOM data and associated non-DICOM data
collected on case report forms should be established and
validated before the clinical trial commences.
DICOM data from the serial imaging of patients and
associated non-DICOM data, including injected activities
and injection times and dates, will potentially have to be
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transferred from the participating centres to a centralised
dosimetry hub for the dosimetry calculations. Validation of
imaging DICOM and associated non-DICOM data transfer
before the trial starts is an essential requirement. Possible
options for the transfer of DICOM data are image databases
and informatics software platforms, such as KHEOPS [38] or
XNAT [39], or the use of file sharing services approved for
such data transfer. Long-term availability and support of
such a service must be ensured.
Patient data must be pseudoanonymised and data
encryption should be ensured prior to data upload to these
services subject to the respective data protection regula-
tions, such as the General Data Protection Regulation
(GDPR). DICOM tags required for the dosimetry processing
may be subject to deletion as part of the pseudoanonym-
isation process. Tests should be included in the data transfer
validation to identify missing DICOM tags. Furthermore,
DICOM tags for injection times and administered activities
are often not populated.
Data transfer methods of non-DICOM data, including
case report forms, must be agreed upon prior to the start of
the trial to ensure that data missing in the DICOM tags are
available at the centralised dosimetry hub.
Dosimetry Calculations and Collation of Results
Recommendations 6: Dosimetry methodologies including
uncertainty analysis should either be standardised across
centres or carried out at a central dosimetry hub.
For a multicentre clinical trial, dosimetry calculations
may be carried out at a centralised dosimetry hub or at the
individual local centre. Local data processing requires
strict standardisation and appropriate uncertainty esti-
mation [40] of all steps involved in the dosimetry calcu-
lations to allow for results to be compared. A central
dosimetry hub can help to reduce the risk of bias that may
be introduced when data are processed locally. This risk
may be mitigated if local dosimetry centres follow com-
mon SOPs for all steps involved in the dosimetry calcula-
tions. Dosimetry data should in any case be centrally
reviewed following the quality assurance procedures
drawn up at the beginning of the study. Local data pro-
cessing and/or dosimetry calculations can potentially
reduce the workload at the central dosimetry or quality
assurance hub.
Uncertainty analysis is particularly important in MRT
because of the current lack of standardisation and the large
uncertainties involved in the image processing steps due to
outlining and quantification. Dosimetry methodologies
must be agreed upon and if different software packages are
used, validation should be carried out to ensure that results
can be compared. Commercially available software pack-
ages are increasingly available, although software devel-
oped in-house may be required, based on the dosimetry
application. Quality assurance on the different systems
should be carried out to provide evidence that the outputs
are comparable.
An essential step in dosimetry calculations is often the
outlining of lesions and organs-at-risk. Studies have shown
that the inter-operator variability of volume delineation can
have a significant impact on the absorbed dose calculations
[13,41] and, therefore, the ability to identify doseeresponse
relationships if that is a trial end point.
Future Directions
Initial studies have shown that inter-system variability
for a given vendor and camera type is low if acquisition
and reconstruction protocols are standardised across
centres so that it may be possible to use the same cali-
bration and correction factors [19,20,22,23]. System pa-
rameters including sensitivity, partial-volume effect and
dead-time correction could be measured on a number of
systems for each vendor and camera type to establish a
quantitative imaging database for gamma cameras. This
would allow for widespread expansion of the existing
imaging network without the requirement of complex site
set-up measurements. Further measurements are required
in large-scale multicentre settings to verify those initial
results.
Nevertheless, the use of global calibration factors from a
database of calibration measurements would require centre
validation measurements to ensure that results from
different centres can be combined and to test the full-
dosimetry chain [4,42].
Conclusions
Large-scale multicentre clinical trials are essential to
investigate the potential for personalised treatment plan-
ning in MRT. Trials require careful planning to ensure that
end points of the trial can be achieved. To encourage patient
participation, optimised and accurate dosimetry protocols
must be established. Expertise and resources at partici-
pating sites must be evaluated and training provided if
necessary. Standardisation of quantification and dosimetry
together with appropriate uncertainty analysis are key to
allow for collation of results across multiple centres. These
steps will facilitate the development of the networks
required to develop personalised treatment planning for
MRT, as is routine for EBRT and brachytherapy.
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